Schizophrenia Flashcards
FGAs
IND:
MOA: DA-2 antagonists. Reduce dopaminergic NTx in the 4 DA pathways. Primary target is the Mesolimbic system to suppress psychosis
BOX: Increased mortality in elderly patients with dementia-related psychosis.
Cardiovascular or infections
CON:
ADR: Anticholinergic/antihistamine. Orthostatic hypotension from Alpha-1 blockade. Hyperprolactinemia. QTc PROLONGATION. Blood abnormalities, seizures, photosensitivity, NMS.
Drug induced movement disorders: Acute dystonia within a week of starting treatment. Treat with Benztropine.
Acute still: May also see drug-induced parkinsonism or akathasia. Treat with anticholinergics.
DA routes activated by FGAs
Mesolimbic: Anti-psychotic effects
Nigrostriatal: EPS
Tuberoinfundibular: Hyperprolactinemia
Mesocortical: Negative s/s and cognitive effects
Higher incidence of neuro side effects; Tardive Dyskinesia, EPS
EPS from FGA
Months after starting. jerky, stiff, writhing of tongue.
IRREVERSIBLE.
D/t increased sensitivity of receptors d/t chronic blockade.
Treat: Switch to SGA
US BOX WARNING OF ALL ANTIPSYCHOTICS
Increased mortality in elderly patients with dementia-related psychosis.
Cardiovascular or infections
Potency
Different sizes, not different efficacies
Chlorpromazine: Low potency, higher ADR
Perphenazine: Medium, medium
Haloperidol: High, low
Neuroleptic Malignant Syndrome
Rare but serious. Extremely high mortality risk a/w FGAs
s/s: Lead pipe rigidity, sudden high fever, arrhythmias, BP abnormal, profuse sweating.
Worse s/s: LOC, seizures, unresponsiveness
Treatment: D/c antipsychotic ASAP. Support, Benzodiazepines. DANTROLENE (muscle relaxer) or BROMOCRIPTINE (DA agonist). Wait 2 weeks, then try lowest effective dose or switch to SGA
TELL DIFFERENCE OF S/S AND TREATMENT AND CAUSES OF SEROTONIN SYNDROME VS NMS
Haloperidol
IND: Schizo, bipolar, delirium, tourette’s
MOA: FGA
BOX: FGA
CON: PD
ADR: QTc PROLONGATION, EPS, anticholinergic, neuroendocrine, sedation, opthalmic
Chlorpromazine
IND: Schizo and HICCUPS MOA: FGA BOX: n/a CON: ADR: QTc PROLONGATION, EPS, anticholinergic, neuroendocrine, sedation, ortho hypotension
Perphenazine
IND: Schizo, N/V
MOA: FGA
BOX: n/a
CON: Bone marrow suppression. Blood dyscrasias. Liver dz
ADR: FGA and agranulocytosis. No QT prolongation
FGA v SGA
Equal efficacy EXCEPT
Clozapine (Clozaril) is the best anti-psychotic but the last line agent.
SGAs
DA-2 and 5HT2A Antagonists.
Stronger affinity for 5HT2A than FGAs
Higher incidence of metabolic syndrome, Lower incidence of EPS
Clozapine
IND: Schizo, last line
MOA: SGA
BOX: SEVERE neutropenia (Clozapine REMS)
Increased mortality in elderly w/dementia
Ortho hypotension; highest risk during initial titration. Has led to cardiac arrest
Seizures
Myocarditis, Cardiomyopathy, and Mitral valve incompetence
CON:
ADR: Fatal agranulocytosis. HTN/hypo, GI, CNS effects, Fever.
Requires adjustments
Clozapine REMS
Risk is dropping WBC or ANC leading to neutropenia and killing the pt. Must be within normal ranges 3500wbc/2000anc.
Cutoffs: WBC less than 3000 or ANC less than 1500; interrupt treatment and monitor daily until resolved.
WBC under 2000 or ANC under 1000, D/c permanently
Provider and pharmacies must enroll to prescribe. Pharmacy requires proof of recent lab.
Weekly monitoring every 6 months
Risperidone
IND: Schizo, bipolar MOA: SGA BOX: n/a CON: ADR: HYPOPROLACTINEMIA IN CHILDREN/ADOLESCENTS. Weight gain.
Olanzapine
IND: schizo, bpd, depression
MOA: SGA
BOX: Post-injection monitoring d/t potential for delirium/sedation from injection
CON:
ADR: ENDOCRINE/METABOLIC; WEIGHT GAIN more than other SGAs. Ortho hypo, gi, weakness. Less EPS than Halo or Risperidone. Decrease Bilirubin. Increase AST/ALT